Ionis Pharmaceuticals Pushes TRYNGOLZA Access as Insurer Requirements Slow Launch

Ionis Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • TRYNGOLZA’s launch is progressing slowly as physicians gain familiarity, while insurers often require patients to try another triglyceride-lowering drug first—even though that step is not on the drug’s label. Ionis is expanding its Quick Start program to bridge patients to covered prescriptions.
  • Ionis is initially targeting nearly 1 million high-risk U.S. patients vulnerable to acute pancreatitis, and CEO Brett Monia described the opportunity as potentially worth billions. TRYNGOLZA also received European approval for severe hypertriglyceridemia.
  • Three months after the U.S. indication expansion, more than 1,500 prescribers had written prescriptions, 24% had prescribed more than once, and 34% of commercial lives had coverage, according to Monia.
  • Five stocks to consider instead of Ionis Pharmaceuticals.

Ionis Pharmaceuticals NASDAQ: IONS is working to accelerate prescriptions for TRYNGOLZA as physicians gain experience with the drug and patients navigate insurance requirements, CEO Brett Monia said at the Jefferies Global Healthcare Conference.

Three months into the drug’s launch for severe hypertriglyceridemia, or severely elevated triglycerides, doctors have shown enthusiasm but have initially prescribed it to relatively few patients each, Monia said. He maintained that TRYNGOLZA represents a multibillion-dollar opportunity while acknowledging that building the market will require education and easier access.

“They’ve been treating only a very small number of patients out of the gate to get familiarity with the drug, to get familiarity with the process,” Monia said.

Focus on Patients at Highest Risk

TRYNGOLZA was initially launched for familial chylomicronemia syndrome, a rare disease, before its indication was expanded to severe hypertriglyceridemia. Monia said the medicine also received European approval for severe hypertriglyceridemia the day before the conference discussion.

Monia said the company is initially focusing on nearly 1 million U.S. patients it considers at high risk of acute pancreatitis because of very high triglycerides or a previous attack. He estimated that a similar number of high-risk patients live in Europe.

Physicians are prioritizing patients who recently experienced acute pancreatitis, although prescriptions are also being written for patients without a history of the condition, Monia said. He added that the drug’s U.S. indication statement includes reductions in acute pancreatitis.

Insurance Access and Quick Start

Jefferies Head of Pharma and Biotech Research Akash Tewari asked whether insurance requirements could slow treatment even when coverage criteria appear broad. Monia said payers require patients to have tried another triglyceride-lowering drug, although that requirement is not part of TRYNGOLZA’s label.

Many high-risk patients are already taking generic treatments without adequate results, Monia said. For newly diagnosed patients, trying another treatment could take three to six months, he added.

Ionis is expanding its Quick Start program, which Monia said provides one or two months of treatment while patients move toward covered prescriptions. The company has relaxed some eligibility criteria, and early signs are encouraging, he said. Monia said the company was pleased with conversion to paid treatment after the program but did not provide a conversion figure.

Ionis is also increasing contact with physicians and using patient education campaigns to raise awareness of triglyceride levels and available treatment, Monia said.

Launch Metrics and Investor Questions

Tewari said investors wanted more information about the number of patients entering the prescription process and converting to paid treatment, particularly after a guidance cut. Monia said Ionis would continue to disclose existing launch metrics and was considering additional ones.

  • More than 1,500 prescribers had prescribed TRYNGOLZA by the end of September, three months after its severe hypertriglyceridemia approval, Monia said.
  • About 24% of prescribers had written more than one prescription by that point, a proportion Monia said was growing.
  • About 34% of commercial lives had coverage for the severe hypertriglyceridemia indication by the end of September, according to Monia.

Monia said Ionis expects coverage to expand and anticipates Medicare contracts next year. He said the company had not identified a suitable cardiovascular drug launch to use as a comparison for TRYNGOLZA’s expected trajectory.

Ionis has seven products on the market across eight indications and four medicines in phase 3 development, Monia said. Alongside TRYNGOLZA, the company is launching DAWNZERA for hereditary angioedema and ZANVASTRO for Alexander disease.

About Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company's research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ionis Pharmaceuticals Right Now?

Before you consider Ionis Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.

While Ionis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines